Targets › INSR
11 programs from 10 companies in 24 trials: 11 Phase 2, 6 Phase 4, 4 Phase 1, 3 Phase 3; Metabolic and endocrine, Ophthalmology, Oncology; next expected readout Dec 2026.
Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. (UniProt, P06213)
Open in Phaseline: the race on INSR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novo Nordisk | Insulin icodec Insulin receptor agonist | INSR | Phase 4 | Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 1 | Jan 2027 |
| Sanofi | Insulin Glargine Insulin receptor agonist | INSR | Phase 4 | Type 2 Diabetes (T2D); Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Type 2 Diabetes … | – |
| Sling Therapeutics | linsitinib Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor | IGF1R, INSR | Phase 3 | Thyroid Eye Disease, TED; Thyroid Eye Disease | Jun 2028 |
| University of Alabama at Birmingham | Insulin Aspart Insulin receptor agonist | INSR | Phase 2 | Diabetes Mellitus, Type 2 | Dec 2026 |
| Mannkind | Insulin Human Insulin receptor agonist | INSR | Phase 2 | Type 1 Diabetes Mellitus; Alzheimer Disease; Type 2 Diabetes; Spinal Cord Injury … | Mar 2027 |
| Gilead Sciences | BIC/LEN FDC Combination of integrase strand transfer inhibitor and capsid inhibitor | INSR, POLLEN | Phase 2 | HIV-1-infection | Dec 2029 |
| Fudan University | Insulin (Novolin 30R) Insulin replacement therapy for glycemic control | INSR | Phase 2 | Pancretic Cancer | – |
| University of California, Los Angeles | Insulin Detemir Insulin receptor agonist | INSR | Phase 2 | Gestational Diabetes | – |
| University of California, Los Angeles | Insulin Human, Isophane Insulin receptor agonist | INSR | Phase 2 | Gestational Diabetes | – |
| DexCom | Insulin Glargine Insulin receptor agonist | INSR | Phase 1 | Type 2 Diabetes | Jan 2027 |
| Gan & Lee Pharmaceuticals. | Insulin Degludec Insulin receptor agonist | INSR | Phase 1 | Type 2 Diabetes | – |
Diabetes Mellitus, Type 2 (5) Type 2 Diabetes (4) Gestational Diabetes (2) Thyroid Eye Disease, TED (1) Thyroid Eye Disease (1) Diabetes Mellitus, Type 1 (1) Pancretic Cancer (1) Type 2 Diabetes (T2D) (1) Metabolic Dysfunction-Associated Steatotic Liver Disease (1) Pregestational Diabetes (1) Diabetes Mellitus in Pregnancy (1) Type 1 Diabetes Mellitus (1)
protein or peptide (8), small molecule (3)
University of California, Los Angeles (2) Sling Therapeutics (1) Novo Nordisk (1) Fudan University (1) Gan & Lee Pharmaceuticals. (1) Sanofi (1) DexCom (1) Mannkind (1) University of Alabama at Birmingham (1) Gilead Sciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.